Leerink Partnrs Comments on Repligen FY2024 Earnings

Repligen Co. (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Repligen in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda expects that the biotechnology company will post earnings per share of $1.55 for the year. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.80 EPS and FY2026 earnings at $2.47 EPS.

Other research analysts have also issued reports about the company. Wolfe Research initiated coverage on Repligen in a research report on Thursday. They issued a “peer perform” rating on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Performance

Shares of RGEN stock opened at $124.73 on Friday. The company’s fifty day simple moving average is $141.54 and its 200-day simple moving average is $144.77. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a market cap of $6.99 billion, a PE ratio of -337.10, a P/E/G ratio of 4.36 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the firm posted $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after acquiring an additional 21,719 shares during the period. Champlain Investment Partners LLC lifted its holdings in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares during the period. Bank of New York Mellon Corp grew its position in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after buying an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after buying an additional 36,773 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.